CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients

The CHIP-AML22 Master protocol has the overall aim of increasing the cure rate in newly diagnosed pediatric de novo AML patients, while avoiding unnecessary toxicity. The linked Quizartinib trial (CHIP-AML22/Quizartinib) is a phase II, single arm, open label, study on the safety, efficacy, pharmacokinetics and pharmacodynamics of quizartinib in combination with chemotherapy and as single-agent after high dose therapy in newly diagnosed pediatric AML patients with a FLT3-ITD mutation and NPM1 wild-type.

Trial Details

NCT ID
NCT06262438
Phase
PHASE2
Sponsor
Princess Maxima Center for Pediatric Oncology
Status
RECRUITING
Cancer Type
Acute Myeloid (AML) Leukemia
Interventions
  • Quizartinib
  • Etoposide
  • Dexrazoxane
  • Mitoxantrone
  • Cytarabine
  • Methotrexate
Locations (sample)
  • Utrecht, Utrecht, Netherlands|52.09083,5.12222

Key Eligibility Criteria

  • Enrollment on CHIP-AML22/Master:
  • Patients must be enrolled on the CHIP-AML22/Master prior to enrollment on CHIP-AML/Quizartinib linked-trial, and may have received a diagnostic wor…
  • FLT3-ITD+ and wild-type NPM1:
  • Presence of FLT3-ITD+ and NPM1 wild type in bone marrow or peripheral blood provided by the local laboratories, as part of standard of care diagnos…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Acute Myeloid (AML) Leukemia Trials on Trialify →